Related Experiment Video
Updated: Aug 20, 2025
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
Mobocertinib in non-small cell lung cancer
Shengwu Liu1,2, Kristen E Lowder3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Drugs of Today (Barcelona, Spain : 1998)
|November 24, 2022
Summary
Mobocertinib effectively treats EGFR Exon 20 insertion mutations in non-small cell lung cancer. This targeted therapy showed significant response rates and progression-free survival in platinum-pretreated patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (EGFR Ex20Ins) historically has limited treatment options.
- Existing tyrosine kinase inhibitors (TKIs) show minimal efficacy against EGFR Ex20Ins.
Approach:
- Mobocertinib (TAK-788) was developed as a targeted TKI specifically for EGFR Ex20Ins.
- Phase I/II clinical trial evaluated mobocertinib in platinum-pretreated NSCLC patients with EGFR Ex20Ins.
Key Points:
- Mobocertinib demonstrated an objective response rate of 28% (95% CI, 20%-37%) in the evaluated cohort.
- Median progression-free survival was 7.3 months (95% CI, 5.5-9.2) and median duration of response was 17.5 months (95% CI, 7.4-20.3).
Conclusions:
- Mobocertinib offers meaningful clinical benefits for patients with EGFR Ex20Ins NSCLC.
- The U.S. FDA granted accelerated approval for mobocertinib in 2021, marking a significant advancement in targeted therapy for this indication.
Keywords:
EGFR (Ex20Ins mutant) inhibitorsHER2 (Ex20Ins mutant) inhibitorsMobocertinibNon-small cell lung cancerSolid tumor therapyMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
215
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
215